| Literature DB >> 18402183 |
A Samie1, J Ramalivhana, E O Igumbor, C L Obi.
Abstract
Campylobacter species are increasingly being recognized as agents of gastroenteritis worldwide. However, data on the pathogenic characteristics of the organism isolated in rural communities in South Africa are lacking. In this study, the prevalence of Campylobacter spp. from diarrhoeal stools, haemolytic and haemagglutinating activities of the isolates, and antibiotic susceptibility profiles, including minimum inhibitory concentration (MIC) patterns to different antibiotics, were determined using the standard microbiological techniques. Campylobacter spp. were isolated from individuals of all age-groups; however, the infection rate was higher among individuals aged less than two years (30.4%). Of 115 Campylobacter strains isolated, polymerase chain reaction (PCR) analysis indicated that 98 (85%) were C. jejuni, while 17 (15%) were C. coli. Seventy-one (62%) of the strains showed haemolysis on human blood, and 80% agglutinated human blood, whereas 22.6% were beta-lactamase-positive. Resistance to antimicrobials, such as erythromycin, ciprofloxacin, vancomycin, and fusidic acid, was high. Increased resistance to macrolide and quinolone antibiotics poses major risks for treatment failure. Haemolytic and haemagglutinating activities may be useful in preliminary characterization of pathogenic strains in settings where Campylobacter-associated infections are common.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18402183 PMCID: PMC2754015
Source DB: PubMed Journal: J Health Popul Nutr ISSN: 1606-0997 Impact factor: 2.000
Antibiotic susceptibility profiles of Campylobacter spp. isolated from diarrhoeal stool samples in Vhembe district
| Class of antibiotics | ATB | Code | Con (μg) | RBP (mm) | No. resistant (%) | MIC range |
|---|---|---|---|---|---|---|
| Penicillins | Penicillin G | PG | 10 | ≤14 | 115 (100) | ≥128 μg/mL–8 μg/mL |
| Amoxicillin | A | 10 | ≤13 | 115 (100) | ND | |
| Cloxacillin | CX | 5 | ≤13 | 103 (89.6) | ND | |
| Ampicillin | AP | 10 | ≤13 | 94 (81.2) | ≥128 μg/mL–8 μg/mL | |
| Cephalosporines | Cephazoline 1st | CZ | 30 | ≤14 | 77 (67) | ND |
| Cefuroxime 2nd | CXM | 30 | ≤14 | 87 (76) | ND | |
| Cefoxitin 2nd | FOX | 30 | ≤14 | 36 (31.4) | ND | |
| Cefotaxime 3rd | CTX | 30 | ≤14 | 33 (28.7) | ND | |
| Ceftriaxone 3rd | CRO | 30 | ≤14 | 8 (7) | ND | |
| Cefepime 4th | CPM | 30 | ≤14 | 9 (8) | ND | |
| Carbapenems | Meropenem | MEM | 10 | ≤13 | 11 (9.6) | ND |
| Imipenem | IMI | 10 | ≤13 | 13 (11.3) | ND | |
| Quinolones | Nalidixic acid | NA | 30 | ≤13 | 59 (51.3) | 128 μg/mL–1 μg/mL |
| Ciprofloxacin | CIP | 5 | ≤15 | 15 (13) | 32 μg/mL–0.25 μg/mL | |
| Lomefloxacin | Lom | 10 | ≤13 | 17 (14.8) | ND | |
| Aminoglycosides | Gentamicin | GM | 10 | ≤12 | 20 (17.3) | 32 μg/mL–0.25 μg/mL |
| Amikacin | AK | 30 | ≤14 | 20 (17.4) | ND | |
| Kanamycin | K | 30 | ≤14 | 21 (18.3) | 32 μg/mL–0.25 μg/mL | |
| Tetracyclines | Tetracycline | T | 30 | ≤14 | 31 (27) | 64 μg/mL–0.25 μg/mL |
| Doxycycline | DXT | 30 | ≤12 | 46 (40) | ND | |
| Macrolides | Erythromycin | E | 15 | ≤13 | 61 (53) | 64 μg/mL–0.5 μg/mL |
| Glycopeptide | Vancomycin | VA | 30 | ≤14 | 115 (100) | ND |
| Others | Fusidic acid | FC | 10 | ≤14 | 113 (98) | ND |
| Rifampicin | RP | 5 | ≤13 | 86 (75) | ND | |
| Chloramphenicol | C | 30 | ≤12 | 24 (21) | 128 μg/mL–0.5 μg/mL | |
| Augmentin | AUG | 30 | ≤14 | 96 (83) | ND | |
| Nitrofurantoin | NI | 300 | ≤14 | 76 (66.1) | ND | |
| Novobiocin | NO | 5 | ≤14 | 115 (100) | ND | |
| Co-trimoxazole | TS | 20 | ≤13 | 42 (36.5) | ND | |
| Trimethoprim | TRP | - | - | ND | ≥128 μg/mL–64 μg/mL | |
| D-cycloserine | DCS | - | - | ND | 4 μg/mL–0.25 μg/mL | |
ATB=Antibiotics; Con=Antibiotic content of the disc; MIC=Minimum inhibitory concentration; ND=Not done; RBP=Resistance break-point
Distribution of study population by age-group and sex and also by rate of isolation of Campylobacter spp. in diarrhoeal stools from hospitals in Vhembe district, South Africa
| Age-group (years) | Males | Females | Total | |||
|---|---|---|---|---|---|---|
| No. (%) of individuals | No. (%) of individuals | No. (%) of individuals | ||||
| 0-2 | 33 (12) | 9 (27.3) | 36 (12.4) | 12 (33.3) | 69 (12.2) | 21 (30.4) |
| 3-5 | 22 (8) | 2 (9) | 25 (8.6) | 6 (24) | 47 (8.3) | 8 (17) |
| 6-9 | 30 (11) | 6 (20) | 21 (7.2) | 4 (19) | 51 (9) | 10 (19.6) |
| 10-19 | 34 (12.4) | 3 (8.8) | 38 (13.1) | 5 (13.1) | 72 (12.7) | 8 (11.1) |
| 20-29 | 46 (16.7) | 11 (23.9) | 52 (18) | 10 (19.2) | 98 (17.3) | 21 (21.4) |
| 30-39 | 47 (17) | 12 (25.5) | 48 (16.6) | 8 (16.7) | 95 (16.8) | 20 (21) |
| 40-49 | 41 (15) | 8 (19.5) | 42 (14.5) | 12 (28.6) | 83 (14.7) | 20 (24.1) |
| 50-60 | 12 (4.4) | 1 (8.3) | 16 (5.5) | 4 (25) | 28 (5) | 5 (17.8) |
| >60 | 10 (3.6) | 0 (0) | 12 (4.1) | 2 (16.7) | 22 (3.9) | 2 (9) |
| Total | 275 (48.7) | 52 (18.9) | 290 (51.3) | 63 (21.7) | 565 (100) | 115 (20.3) |